Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

(WDRB) -- A nationwide shortage of popular weight loss medications ... of their drugs. The companies argue that some compounded products are ineffective or even dangerous. Eli Lilly stated ...

27,587 people played the daily Crossword recently. Can you solve it faster than others?27,587 people played the daily Crossword recently. Can you solve it faster than others? Suits ' Gabriel Macht ...

FILE PHOTO: An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan McDermid/File Photo · REUTERS / Reuters JPMorgan analyst ...

Eli Lilly & Co.’s ... demand for its popular weight-loss and diabetes shots for the second quarter in a row. Demand for Lilly’s obesity and diabetes drugs Zepbound and Mounjaro, which are ...

Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker's shares closed more than 6% lower on ...